Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
Brain and Central Nervous System Tumors
About this trial
This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring adult oligodendroglioma, adult anaplastic oligodendroglioma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven anaplastic oligodendroglioma OR Histologically proven anaplastic mixed glioma (oligoastrocytoma) provided there is an unequivocal and substantial (at least 25%) oligodendroglial element No systemic or leptomeningeal metastases (excluding contiguous leptomeninges) PATIENT CHARACTERISTICS: Age 18 and over Performance status Karnofsky 60-100% Life expectancy Not specified Hematopoietic Granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic Bilirubin no greater than 1.5 times upper limit of normal (ULN) OR SGOT no greater than 2 times ULN Renal Creatinine no greater than 1.5 times ULN Cardiovascular LVEF at least 50% Pulmonary DLCO at least 50% of predicted Other No other serious illness that would preclude study therapy No other concurrent malignancy except basal cell skin cancer or carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior systemic chemotherapy Endocrine therapy Not specified Radiotherapy No prior cranial radiotherapy Surgery Prior complete or partial resection, open biopsy, or stereotactic biopsy allowed
Sites / Locations
- University of Alabama Comprehensive Cancer Center
- Stanford University Medical Center
- Evanston Northwestern Health Care
- Loyola University Medical Center
- Memorial Sloan-Kettering Cancer Center
- Tom Baker Cancer Center - Calgary
- Cancer Care Ontario-London Regional Cancer Centre